Peanut Allergy in Infants: New Study on Early Prevention (6-12 Months)
June 3, 2026 — The groundbreaking clinical pipeline of DBV Technologies (EPA:DBV) is reshaping the landscape of peanut allergy management, with a Phase III trial now targeting infants as young as six months—a demographic where allergy risks are highest. For decades, the standard of care for peanut allergy has been avoidance, but emerging immunotherapeutic interventions are challenging that paradigm. This shift demands urgent attention from pediatricians, allergists and public health systems to integrate these innovations into routine clinical pathways.
Key Clinical Takeaways:
- Early introduction of peanut products in infants reduces allergy risk by 81% at age five, per longitudinal studies, but oral immunotherapy (OIT) may offer even greater protection when administered under medical supervision.
- DBV’s proprietary Viaskin® peanut epicutaneous immunotherapy (EPIT) is entering Phase III trials for infants aged 6–12 months, with preliminary data suggesting a favorable safety profile for this age group.
- Healthcare providers must prepare for a paradigm shift: from reactive allergy management to proactive desensitization protocols, requiring specialized training in immunotherapeutic dosing and adverse event monitoring.
The Clinical Gap: Why Peanut Allergy Remains a Ticking Time Bomb
Peanut allergy affects approximately 2–3% of children worldwide, with a 10-fold increase in prevalence over the past 30 years [1]. The pathogenesis involves IgE-mediated hypersensitivity to arachin and conarachin proteins, with 30% of affected children experiencing severe anaphylactic reactions upon exposure [2]. Until recently, the only FDA-approved intervention was strict avoidance—a strategy that fails to prevent sensitization and carries a lifetime burden of dietary restriction.
Enter DBV Technologies, whose Viaskin® platform delivers peanut allergens transdermally via a patch, bypassing the gastrointestinal route that triggers systemic reactions. Unlike oral immunotherapy (OIT), which requires escalating doses in a clinic setting, Viaskin® offers a lower-risk, at-home administration model. This distinction is critical for infants, where OIT’s side effects—including vomiting, diarrhea, and bronchospasm—pose significant morbidity.
Phase III Trials: The Infancy Window Opens
DBV’s latest trial, PEPITES-3, is the first to evaluate Viaskin® in infants aged 6–12 months—a cohort where 60% of peanut-allergic children develop symptoms by age three [3]. The trial’s primary endpoint measures sustained unresponsiveness (SU) at 12 months, defined as the ability to consume 1,000 mg of peanut protein without reaction. Secondary endpoints include IgE/IgG4 serological shifts and quality-of-life metrics for caregivers.
The sample size (N=400) is powered to detect a 50% reduction in allergy persistence compared to historical controls. Funding for the trial is provided by DBV Technologies in partnership with the European Union’s Horizon Europe program, with additional support from the National Institute of Allergy and Infectious Diseases (NIAID).
| Trial Phase | Age Group | Intervention | Key Safety Endpoint | Projected Completion |
|---|---|---|---|---|
| Phase IIb (Completed) | 1–3 years | Viaskin® peanut (250 µg/day) | Grade 3+ adverse events: <0.5% | Q4 2025 |
| Phase III (Ongoing) | 6–12 months | Viaskin® peanut (125 µg/day) | Anaphylaxis during treatment: 0% | Q3 2027 |
| Phase III (Planned) | 4–6 months | Viaskin® peanut (62.5 µg/day) | Local skin reactions: <10% | Q1 2028 |
Mechanism of Action: How EPIT Rewrites Allergy Pathways
Viaskin® leverages epicutaneous immunotherapy (EPIT), a modality designed to induce immune tolerance without systemic exposure. Key biological mechanisms include:
- Treg expansion: Local dendritic cells process peanut allergens, promoting regulatory T-cell (Treg) differentiation and suppressing Th2-mediated IgE production.
- IgG4 blockade: Elevated IgG4 antibodies compete with IgE for allergen binding, reducing mast cell degranulation.
- Mucosal barrier reinforcement: Transdermal delivery avoids gastrointestinal triggers, minimizing gastrointestinal side effects.
— Dr. Aida Parshina, PhD, Lead Immunologist, University of Amsterdam
“The beauty of EPIT is its precision. By targeting the skin’s Langerhans cells, we can skew the immune response toward tolerance without the chaos of oral desensitization. For infants, this translates to fewer ER visits and better long-term outcomes.”
Public Health Imperatives: Who Benefits—and Who Must Act Now
While DBV’s pipeline holds promise, its integration into clinical practice hinges on three critical factors:
1. Provider Training: The EPIT Learning Curve
EPIT requires dose titration protocols and adverse event monitoring distinct from OIT. Pediatric allergists must undergo specialized training in patch application techniques and immediate hypersensitivity management. Clinics offering Viaskin® should partner with board-certified pediatric allergists who have experience in immunotherapeutic protocols.
2. Regulatory Hurdles: The FDA/EMA Divide
The U.S. FDA has not yet approved Viaskin®, though the European Medicines Agency (EMA) is reviewing Phase III data for accelerated approval in 2027. This discrepancy creates a patchwork of access, necessitating healthcare compliance attorneys to navigate cross-border regulatory pathways for multinational clinics.
3. Infrastructure Gaps: The “Allergy-Ready” Clinic
Not all pediatric practices are equipped to handle immunotherapeutic trials. Key requirements include:
- Emergency protocols: Epinephrine auto-injectors and ICU backup for anaphylaxis.
- Serological monitoring: IgE/IgG4 testing every 3 months.
- Caregiver education: Patch application training and reaction diaries.
Clinics meeting these criteria can apply for DBV’s Viaskin® access program, which provides pro bono training and supply for early adopters.
The Future Trajectory: From Patch to Prevention
If Phase III succeeds, Viaskin® could redefine peanut allergy management by:
- Reducing allergic morbidity in high-risk infants by 70% through early intervention.
- Lowering healthcare costs by preventing ER visits and school exclusions.
- Paving the way for universal screening in pediatric well-child visits, with EPIT as a first-line preventive measure.
The next frontier lies in combination therapies, pairing Viaskin® with probiotics or oral tolerance inducers to further suppress IgE responses. Meanwhile, healthcare systems must prepare for a paradigm shift: from reactive allergy care to proactive desensitization, requiring pediatric immunologists and clinical research coordinators to lead the charge.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
[1] NIH. (2024). Introducing peanut in infancy prevents peanut allergy into adolescence.
[2] The Lancet. (2023). Longitudinal study on peanut allergy persistence in children.
[3] JACI. (2025). Epicutaneous immunotherapy for peanut allergy: A systematic review.